Supplement Facts Check

Dose reference table

Criterion 4 checks a label’s dose against the range human trials actually used for the outcome the product claims. This is that table: 55 rows, 31 with a range set. Rows without one record why, including the date the literature was searched.

IngredientFormDaily range Outcome measured, and basisPubMed ID
L-glutaminefree-form15 gpost-infectious IBS-D symptom severity and permeability; 5g TID for 8 weeks (Zhou 2019); PubMed verified 2026-09-07 — confirmed: 5 g three times daily (15 g/d) for 8 wk, n=106 completing, primary endpoint met by 79.6% versus 5.8% on placebo, with lactulose/mannitol ratios normalised (Zhou 2019)30108163
L-glutaminefree-form≥ 30 gintestinal permeability; meta-analysis found no overall effect, significant reduction only in subgroup ≥30g/day; PubMed verified 2026-09-07, full text checked 2026-09-22 (PMID 39397201, PMC11471693) — the overall null result is confirmed (WMD -0.00, 95% CI -0.04 to 0.03, 10 studies, 352 participants). The 30 g/day reading is confirmed correct: Methods defines the subgroup as "≥ 30 g/d," Table 1 headers it the same way, and Table 2's per-study doses are all gram-scale (30 g/day, 24 g/day, 20 g/day, 30.5 g/day, etc.) -- nowhere near milligram range. The source paper's Discussion and Conclusion nonetheless repeat "30 mg/day," a real uncorrected error, not an abstract-only artifact.Unresolved problem in the source. UNRESOLVED: the subgroup statistic is printed as WMD -0.01 with 95% CI -0.10 to -0.08 (n=5 studies), an interval that excludes its own point estimate; full text gives no way to determine the correct figures. SEPARATE INCONSISTENCY: Table 1 defines duration subgroups as ≥4 weeks / <4 weeks, but the Discussion/Conclusion instead describe the significant effect as occurring in interventions "less than 2 weeks" -- a cutoff absent from the paper's own methodology. Flag this if this row is ever used for a duration-based judgment, not just dose.39397201
Zinc carnosinepolaprezinc75 mgprevention of NSAID-induced intestinal permeability increase; 37.5mg BID for 5 days, crossover n=10 (Playford 2006); tested prevention not repair; PubMed verified 2026-09-07 — confirmed: 37.5 mg twice daily (75 mg/d) for 5 d, randomised crossover, n=10 healthy volunteers, preventing the threefold indomethacin-induced rise in lactulose/rhamnose ratio. Formal citation is Gut 2007;56:168-75, epub 200616777920
Slippery elminner bark powderNo range setno adequate human trial identified; RCT-filtered search returns only multi-herb proprietary blends (PMID 29958034, null for GI symptoms) and other Ulmus species; PubMed verified 2026-09-07 — 10 records, none isolating slippery elm on a gut outcome. The null multi-herb 'detox' RCT already cited is PMID 29958034; a second multi-herb formula containing slippery elm alongside curcumin, aloe, glutamine, pectin, guar gum and peppermint reported large improvements but was an uncontrolled pre-post study, not randomized (Ried 2020, PMID 32151878), and cannot attribute effect to any one component29958034
Marshmallow rootroot extractNo range setno adequate human trial identified for gut outcomes; RCT-filtered search returns candidiasis, cough syrup and topical studies only; remaining evidence is animal and in vitro; PubMed verified 2026-09-07 — 4 records, none testing Althaea root extract on a gut outcome. Trap to avoid: PMID 25951410 is a genuine randomized crossover reporting reduced ileostomy output (n=28), but it tested confectionery marshmallows and attributes the effect to gelatine. It is indexed under Althaea and must not be read as evidence for marshmallow root extract—
DGL licoriceGutGard branded extract150 mgGERD symptoms and quality of life; 75mg BID post-meals for 4 weeks, n=200 (Raj 2025); branded flavonoid-rich DGL standardized to glabridin >=3.5%, does not transfer to generic DGL; PubMed verified 2026-09-07 — n=200, 28 d, and the glabridin >=3.5% w/w standardisation are all confirmed, as is the benefit on GERD quality of life (p=0.014), heartburn and regurgitation. However the 150 mg dose is NOT stated in the abstract; like the peppermint row, the figure rests on a source this verification could not reach39929150
Collagen peptideshydrolyzed type I/IIINo range setno positive-outcome controlled trial identified; 10g/day 7 days null for GI integrity and symptoms, n=20 crossover (PMID 36370176); 20g/day 8wk reported benefit but open-label single-arm, 14/40 completed (PMID 35639457); both studies include authors affiliated with the collagen manufacturer; PubMed verified 2026-09-07 — cited PMID 36370176 confirmed: 10 g/d for 7 d, n=20 crossover, no effect on lactulose/rhamnose ratio, I-FABP, inflammatory markers or subjective GI symptoms; two authors are employed by the collagen manufacturer (Rousselot BV)36370176
Butyratesodium butyrateNo range set300mg/day null in pediatric IBD 12wk (Pietrzak 2022); no positive-outcome human trial verified; PubMed verified 2026-09-07 — cited PMID 36014789 confirmed: 150 mg twice daily (300 mg/d) for 12 wk added to standard therapy in newly diagnosed paediatric IBD, n=72, no difference in remission rate or disease activity versus placebo36014789
ButyratetributyrinNo range setno PubMed-indexed positive-outcome trial identified; a 100-200mg 21-day pilot published outside PubMed reported null results for butyrate levels and microbiome with a triglyceride increase at 200mg; 4g/day depression trial is a protocol with no results; remaining evidence in vitro and animal; PubMed verified 2026-09-07 — only 3 RCT-indexed records exist. The one testing isolated tributyrin (6.53 g, acute meal, n=12) was null for GLP-1, GIP, PYY and neurotensin, the authors concluding dietary butyrate did not stimulate gut hormone secretion (PMID 26178726); the other two embed tributyrin in multi-component immunonutrition feeds and found no benefit (PMID 16832133, 21044933). A 2025 Parkinson's study at 1500 mg/d is open-label, uncontrolled and has no gut outcome (PMID 41271518); the 4 g/d depression protocol is PMID 4124839726178726
Berberineberberine HCl400 mgIBS-D diarrhea frequency, abdominal pain, urgency; 8 weeks (Chen 2015; 400mg/day given as 200mg BID); PubMed verified 2026-09-07 — confirmed: 400 mg/d as 200 mg twice daily for 8 wk, n=132 randomised of 196 recruited, significant reductions in diarrhoea frequency (P=0.032), abdominal pain and urgency (both P<0.01)26400188
Quercetinquercetin dihydrate≥ 500 mgsystemic inflammation (CRP reduction) per meta-analysis at >=500 mg/day (PMID 28537580); no RCTs identified for intestinal permeability — gut-barrier evidence is preclinical only; PubMed verified 2026-09-07 — a clinical-trial-filtered search for quercetin with intestinal permeability, gut barrier, leaky gut or irritable bowel returns zero records. The gut-barrier claim rests entirely on preclinical work; PubMed verified 2026-09-07 — confirmed: 7 RCTs across 10 treatment arms, CRP reduced by 0.33 mg/l overall and by 0.34 mg/l in the subgroup at or above 500 mg/d. Caveat: the same meta-analysis reports that meta-regression found no association between CRP change and dose, which weakens 500 mg/d as a genuine threshold rather than a subgroup artefact28537580
Aloe verainner leaf gelNo range setno usable reference range; IBS extract trial null vs inulin control, n=160, dose not stated in abstract (Ahluwalia 2020); positive UC trial used 200mL/day liquid gel (Langmead 2004), not convertible to capsule mg; PubMed verified 2026-09-07 — 8 RCT-indexed records, none yielding a convertible capsule dose. The positive UC trial dosed 100 mL twice daily of liquid gel (Langmead 2004, PMID 15043514); a second IBS trial of AVH200 extract, n=68 for 4 wk, missed its primary endpoint (p=0.09) with positive secondary signals and no dose in the abstract (Storsrud 2015, PMID 26405698); the remaining positives are multi-ingredient formulas where aloe is combined with inulin and lactitol (PMID 31686768) or with senna (PMID 39951927)32314514
N-acetyl glucosamineNAGNo range settested and null; no significant effect on faecal biomarkers of mucosal damage in randomized multi-arm trial, n=24 arm, 14 days (Chandwe 2024, P=0.67); dose not stated in abstract; open-label IBD pilots at 3-6 g/day; Phase 3 IBS-D trial registered at 300mg/day (NCT02504060), no published results located; PubMed verified 2026-09-07 — cited PMID 38632262 confirmed: NAG arm of a multi-arm phase II trial in children with severe acute malnutrition, n=24, 14 days, effect on the composite faecal mucosal-damage biomarker -0.20 (90% CI -1.01 to 0.60), P=0.67, while teduglutide was the only arm to reach the trial's pre-specified threshold38632262
Ashwagandharoot extract standardized600 mgstress and serum cortisol reduction; 300mg BID for 60 days, n=64 (Chandrasekhar 2012); extract described as high-concentration full-spectrum, brand not named in paper; no gut-outcome trials identified; NOT YET VERIFIED against PubMed as of 2026-09-07. This row sets no gut reference range (it is a stress and cortisol outcome with no gut trial identified), so it cannot decide a criterion 4 score, and it was deprioritised in the verification pass. Verify before relying on it.23439798
L-theaninefree-form200–400 mgstress and anxiety reduction; 200-400mg/day per systematic review of 9 RCTs (Williams 2020); no gut-outcome trials identified; NOT YET VERIFIED against PubMed as of 2026-09-07. This row sets no gut reference range (it is a stress and anxiety outcome with no gut trial identified), so it cannot decide a criterion 4 score, and it was deprioritised in the verification pass. Verify before relying on it.31758301
MagnesiumglycinateNo range setno adequate human trial identified for gut outcomes; constipation evidence is for magnesium oxide (PMID 32969946), a different salt; PubMed verified 2026-09-07 — search returns 6 records and none is a human gut-outcome trial: a 1994 bioavailability crossover in ileal-resection patients measuring absorption, not a gut outcome (PMID 7815675); rat ileum motility (PMID 37636381); two Caco-2 cell studies (PMID 32098378, 41599937); a marine-multimineral tolerability trial using bisglycinate only as an in vitro comparator (PMID 38608850); and a single hypomagnesemia case report (PMID 42567449)—
MagnesiumcitrateNo range setno adequate human trial identified for supplement-dose use; available trials are colonoscopy bowel-prep protocols at purgative doses, usually combined with sodium picosulfate; PubMed verified 2026-09-07 — all 8 RCT-indexed records are colonoscopy or surgical bowel preparation at purgative doses, typically combined with sodium picosulfate or sennosides (e.g. PMID 25019969, 27782976, 20799286, 9496494). None tests supplement-dose magnesium citrate for a gut outcome—
Astaxanthinnatural haematococcusNo range settested and null for gut outcomes. CORRECTION 2026-09-07: this row previously read 'no gut-outcome trial identified', which was wrong — two randomized placebo-controlled trials in functional dyspepsia exist. 16 and 40 mg/d for 4 wk, n=132 across three arms, found no difference between groups on the primary GSRS endpoint of abdominal pain, indigestion and reflux, with a secondary signal on reflux at 40 mg only (Kupcinskas 2008, PMID 18467083); 40 mg/d, n=44, found gastric inflammation fell in both arms with no between-group difference and no change in H. pylori density or interleukins (Andersen 2007, PMID 17521392). Both are null on their primary endpoints, so under the positive-outcome rule no reference range is set and the criterion 4 exclusion is unchanged — but the reason is 'tested and did not work', not 'never studied'. Remaining human RCTs are for skin ageing and oral submucous fibrosis (5mg BID)18467083
Piperineblack pepper extract10–15 mgdosed as absorption enhancer, not for an independent outcome; 10mg/day with 1g curcuminoids (PMID 25618800) and 15mg/day (PMID 25688638); excluded from criterion 4 as no trial tests piperine against a gut outcome of its own; NOT YET VERIFIED against PubMed as of 2026-09-07. This row sets no gut reference range (it is an absorption enhancer excluded from criterion 4), so it cannot decide a criterion 4 score, and it was deprioritised in the verification pass. Verify before relying on it.25618800
Curcuminstandardized extract1500–2000 mgUC disease activity and relapse prevention; 1500mg/day 8wk (Sadeghi 2020, PMID 31802559) and 2000mg/day 6mo (Hanai 2006); both as add-on to mesalamine/sulfasalazine; PubMed verified 2026-09-07 — both trials confirmed, but they are not the same outcome and the row should not be read as one range. Sadeghi 2020 gave 1500 mg/d for 8 wk to n=70 with ACTIVE mild-to-moderate UC, improving disease activity, hs-CRP and ESR. Hanai 2006 gave 2000 mg/d (1 g twice daily) for 6 mo to n=89 with QUIESCENT UC as maintenance, cutting relapse from 20.5% to 4.7% (P=0.040). Under the outcome-specific rule, a product claiming symptom relief scores against 1500 mg and one claiming remission maintenance against 2000 mg17101300
CurcuminCurcugen branded extract500 mggeneral digestive symptoms (GSRS) and anxiety; 500mg once daily 8wk, n=79 (Lopresti 2021); no effect on microbiota or SIBO; branded enhanced-bioavailability extract, does not transfer to standard 95% extract; PubMed verified 2026-09-07 — confirmed: 500 mg once daily for 8 wk, n=79 randomised and 77 analysed, significant reduction in GSRS total and in DASS-21 anxiety, with no effect on microbiota or SIBO. Not previously noted: one author is affiliated with DolCas Biotech, which manufactures Curcugen33478482
Saccharomyces boulardiilive strain CNCM I-745500–600 mg/dayH. pylori eradication support; acute viral diarrhoea range set by independent adult randomised trials of CNCM I-745, all dosing in milligrams of preparation: 250 mg twice daily for H. pylori eradication support (Seddik 2019, PMID 30694338, open-label); 600 mg daily for acute viral diarrhoea (Salazar-Parra 2023, PMID 37400812). Scoreable on criterion 4 under methodology v1.12 where a label declares milligrams; still excluded where a label declares CFU only. Kotowska 2005 (PMID 15740542) dosed 250 mg twice daily for antibiotic-associated diarrhoea prevention in children, n=269 enrolled and 246 analysed, RR 0.3 (95% CI 0.2-0.7), and is consistent with the range but is a paediatric trial. Maev 2025 (PMID 40884341) dosed 500 mg twice daily for SIBO but administered Enterol, a Biocodex product, and Biocodex manufactures Florastor: recorded here and excluded from setting the range under the independence rule. Author affiliations of the three range-setting trials are academic and hospital only; funding statements were not verifiable from the abstracts and are recorded as unverified. PubMed verified 2026-09-26 Corrected 2026-11-19: Sjomina 2023 (PMID 37942999, 500 mg twice daily) no longer sets the range. Its conclusion is that S. boulardii does not increase eradication, and its positive 10-day and adverse-event results lost significance after Type I error adjustment, so it fails the positive-outcome rule. Upper bound moves from 1000 to 600 mg/day. Salazar-Parra 2023 is a weak positive: no change in symptom severity, with a patient global improvement difference on day 4 (P=0.03).30694338;37400812
Lactobacillus rhamnosus GGlive strain10000000000–20000000000 CFU/dayantibiotic-associated diarrhoea prevention in children VERIFIED against PubMed 2026-09-27, replacing the unverified 2026-09-07 row that set no range. Range set by Vanderhoof 1999 (PMID 10547243), a double-blind randomised trial of antibiotic-associated diarrhoea prevention in children aged 6 months to 10 years, n=202 enrolled and 188 completing, dosing 1x10^10 to 2x10^10 CFU/day. 25 placebo-treated versus 7 LGG-treated children had diarrhoea, and LGG significantly reduced stool frequency and increased consistency by day 10. Author affiliations are University of Nebraska paediatrics only; the funding statement was not verifiable from the abstract and is recorded as unverified rather than asserted independent. CONTESTED: the Cochrane review of probiotics for acute infectious diarrhoea (Collinson 2020, PMID 33295643, 82 studies and 12,127 participants, 11,526 of them children) found probiotics probably make little or no difference to the number of people with diarrhoea lasting 48 hours or longer, with LGG examined in a pre-specified subgroup. Recorded under the contested-literature rule; it does not set the range, since ranges come from positive-outcome trials, but a reader should weigh it against this row10547243
Bifidobacterium longumlive strainNo range setexcluded from criterion 4 per methodology; probiotic trial dosing is strain-specific and reported inconsistently as mg or CFU, not convertible to label CFU; NOT YET VERIFIED against PubMed as of 2026-09-07. This row sets no gut reference range (it is a probiotic excluded from criterion 4, carrying no PMID), so it cannot decide a criterion 4 score, and it was deprioritised in the verification pass. Verify before relying on it.—
Peppermint oilenteric-coated561 mgIBS abdominal pain; 187mg TID for 8 weeks (Merat 2010; dose inferred from Colpermin formulation, not stated in abstract); largest trials null at 182mg TID; PubMed verified 2026-09-07 — the inference this row already flags is confirmed as unresolved: Merat 2010 states only 'one capsule of Colpermin three times daily' for 8 wk in n=90. No milligram dose appears in the abstract, so 561 mg/d rests entirely on the Colpermin formulation being 187 mg per capsule19507027
ZincpicolinateNo range setno trial identified for this form; permeability normalization reported with zinc sulfate 110mg TID for 8 weeks in Crohn's (Sturniolo 2001); other gut trials use gluconate or elemental zinc in diarrhoea and HIV; doses inconsistently reported as compound vs elemental; PubMed verified 2026-09-07 — 4 RCTs indexed for this form, none with a gut outcome: a 1987 absorption comparison at 50 mg elemental zinc (PMID 3630857), a null multi-nutraceutical depression trial (PMID 30699842), COPD antioxidant status at 22 mg (PMID 18295467), and taste disorder at 29 mg TID (PMID 12132610)—
Magnesiumoxide1500 mgchronic idiopathic constipation; 1.5g MgO daily for 28 days, n=90, 68.3% response vs 11.7% placebo (Morishita 2021); dose stated as MgO compound weight not elemental; PubMed verified 2026-09-07 — confirmed on dose, duration and response rates. Precision correction: n=90 is the whole three-arm trial (senna 1.0 g, MgO 1.5 g, placebo), so the MgO arm is roughly 30 participants, not 9032969946
XylooligosaccharideXOS from corn cob1.4–8 gbifidobacteria increase in healthy adults; 1.4 and 2.8 g/d for 8 wk n=32 (Finegold 2014); 5 g/d for 4 wk n=60 (Lecerf 2012, PMID 22264499); 8 g/d for 21 d (Childs 2014, PMID 24661576); 4 g/d T2DM trial (Sheu 2008) not a gut outcome; INU-XOS arm in Lecerf used 1 g XOS + 3 g inulin and does not set the range; PubMed verified 2026-09-07 — all three cited trials confirmed on dose, duration and sample size: Finegold 2014 n=32 at 1.4 and 2.8 g/d for 8 wk with bifidobacteria up in both arms versus placebo and 2.8 g significantly greater; Lecerf 2012 n=60 at 5 g/d for 4 wk; Childs 2014 at 8 g/d for 21 d, which also raised bowel movement frequency. The INU-XOS arm is confirmed as 3 g inulin + 1 g XOS24513849
Inulinchicory root12 gfunctional constipation; 12 g/d for 4 wk, randomized double-blind placebo-controlled crossover, n=39 Rome III, improved stool frequency and constipation-related quality of life (Puhlmann 2025, BMC Gastroenterol, PMID 41233756); 12 g/d as 3x4 g for 4 wk, randomized double-blind placebo-controlled crossover, n=44, increased stool frequency vs placebo (Micka 2017, Int J Food Sci Nutr 68:82-89, PMID 27492975); both trials used chicory-derived inulin. Not a probiotic: assessed under criterion 4 normally; PubMed verified 2026-09-07 — both trials confirmed on dose, duration, design and sample size Independence, added 2026-11-19: Micka 2017 has two BENEO-Institute co-authors (BENEO makes Orafti chicory inulin, the product tested), and three of ten Puhlmann 2025 authors are at Sensus B.V. (Royal Cosun), a chicory-inulin producer, so the range rests on the weaker basis under the independence rule. The trial also reports a carry-over effect in its crossover, addressed by a first-period parallel analysis that supported the result. An independent trial at the same 12 g/d dose (Glibowski 2020, PMID 32319465) is recorded in its own row.41233756
Pomegranate extractellagitannin-standardized fruit extract320–656 mg phenolicsgut microbiota modulation and reduced endotoxemia in overweight-obese adults; 656 mg phenolics/d for 3 wk crossover n=49 reduced plasma LBP and increased Faecalibacterium, Odoribacter and Butyricicoccus (Gonzalez-Sarrias 2018, PMID 29665619); 320 mg phenolics/d for 1 mo crossover n=50 modulated microbiota in metabolic syndrome but the effect depended on concurrent drug therapy (Cortes-Martin 2021, PMID 33458928); a dose-response trial found 160 mg phenolics/d null, with effects only at 640 mg/d and only in urolithin metabotype B subjects (Gonzalez-Sarrias 2017, PMID 27879044), so 160 mg does not set the range. Doses are phenolic weight, not extract weight: comparing a label to this range requires both the extract weight and a stated standardization percentage; PubMed verified 2026-09-07 — all cited trials confirmed; METHODOLOGY v1.7 — this is the governing range for pomegranate extract. It is independent of any manufacturer and tests the ingredient itself, so under the evidence hierarchy it takes precedence over the finished-product row below29665619
Pomegranate extractMAPP, as formulated in the DS-01 multi-species synbiotic400 mg extractGI quality of life, bloating, gas, abdominal discomfort, constipation and regularity; 400 mg Indian pomegranate extract given with 53.6 billion AFU multi-species probiotic for 6 wk, randomized placebo-controlled n=350 (Allegretti 2026, PMID 41599868); same formulation for 91 d n=32 increased faecal butyrate, urinary urolithin A and microbial diversity (Napier 2025, PMID 40944126). Finished-product trials: the pomegranate component is not tested in isolation, so this range does not transfer to pomegranate extract generally. Several authors of both trials are employees of the manufacturer (Seed Health); PubMed verified 2026-09-07 — both trials confirmed; METHODOLOGY v1.7 — this row NO LONGER SETS A RANGE. It fails both hierarchy rules: the trials dose a whole multi-ingredient synbiotic, so the effect cannot be attributed to the pomegranate component (the same rule that bars the multi-herb formulas elsewhere in this table), and their authors include employees of the manufacturer while an independent ingredient-level range exists. Retained as evidence of the finished product, not as a dose reference41599868
Bifidobacterium longum subsp. longum 35624live strain (formerly B. infantis 35624)100000000 CFU/dayIBS symptom relief: abdominal pain, bloating, gas range set by the two positive-outcome trials of this strain, both manufacturer-linked. Whorwell 2006 (PMID 16863564, n=362 women with IBS) is the pivotal encapsulated dose-ranging trial: 1x10^8 CFU/day significantly superior to placebo for abdominal pain, composite score, bloating, bowel dysfunction, incomplete evacuation, straining and passage of gas, while 1x10^6 and 1x10^10 were NOT different from placebo. Dose response is therefore non-monotonic and 1x10^8 is the only capsule dose shown to work. O'Mahony 2005 (PMID 15765388, n=77) found 1x10^10 CFU/day effective but delivered in a malted milk drink, not a capsule, so it does not establish 1x10^10 for an encapsulated product. INDEPENDENCE: both trials carry authors affiliated with the manufacturer (Charbonneau, Procter & Gamble, on Whorwell 2006; Kiely, Alimentary Health, on both). They set the range only because no independent positive trial was identified, and are flagged here as the weaker basis. CONTESTED: an independent meta-analysis (Yuan 2017, PMID 28166427) found single-strain B. infantis 35624 did not significantly affect abdominal pain, bloating/distention or bowel habit satisfaction; recorded per the contested-literature rule but does not set the range. PubMed verified 2026-09-2716863564;15765388
Bacillus subtilis DE111live strainNo range setno adequate human trial identified no adequate human trial identified for a gastrointestinal outcome as of 2026-09-27. PubMed search 'DE111[All Fields] AND Bacillus subtilis' returned 12 records, reviewed in full. Two measured gastrointestinal endpoints and both were null: Freedman 2021 (PMID 33671071, 4-week randomised double-blind placebo-controlled pilot in healthy adults) reported perceived gastrointestinal health, microbiota, IL-6, sIgA and plasma zonulin 'largely unaffected', noting the study may have been underpowered; Townsend 2018 (PMID 30049931, 1 billion CFU/day in collegiate athletes) reported no effect on gut permeability. Trotter 2020 (PMID 33161737) measured blood lipids and endothelial function, not a gut outcome. Colom 2023 (PMID 36790091) examined ileostomy metabolomics and is authored by Deerland Probiotics and Enzymes, the manufacturer of DE111, so it is manufacturer-linked as well as not being a clinical outcome trial. NO paediatric trial of DE111 was identified at any dose, which matters because the products carrying it in this sample are marketed to children. Under the positive-outcome-trials-only rule these set no range—
Bacillus coagulans GBI-30, 6086 (BC30)live strainNo range setIBS abdominal pain and bloating; no dose stated in the available record only trial identified for this strain at a digestive outcome is Hun 2009 (PMID 19332970), a randomised double-blind placebo-controlled trial in 44 IBS patients dosed once daily for 8 weeks, reporting significant within-group improvement in abdominal pain and bloating. It sets NO numeric range here because the abstract states no CFU dose at all, so nothing verifiable can be converted to a label comparison. Two further weaknesses are recorded: baseline values differed significantly between groups, so the authors ran within-group rather than between-group analysis, and the authors describe the result as preliminary and call for larger trials. Full text was not retrieved; if the dose is stated in the body of the paper, this row should be revisited and a range added. PubMed search 'Bacillus coagulans GBI-30 6086 randomized controlled trial abdominal pain bloating irritable bowel' returned this single record on 2026-09-2719332970
Bacteriophage cocktail (PreforPro)LH01, LL5, T4D and LL12 phage preparation15 mg/daygut microbiota modulation in adults with self-reported gastrointestinal distress PreforPro, the four-phage cocktail LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae and LL12-Myoviridae sold by Deerland. Range set by Febvre 2019 (PMID 30897686), a randomised double-blind placebo-controlled crossover trial, n=36 analysed, one 15 mg capsule daily for 28 d in adults with self-reported gastrointestinal distress: fecal Escherichia coli significantly reduced (p=0.03) and taxa mapping to the butyrate-producing genera increased, while short-chain fatty acids, fecal and plasma inflammatory markers and lipids were unchanged apart from a fall in circulating IL-4. Flagged as the weaker basis under the independence rule: the capsules were prepared by Deerland, the manufacturer of the ingredient, the funding statement was not verifiable from the text retrieved, and no independent trial of this cocktail exists. Two further trials are recorded but do not set the range. Gindin 2018 (PMID 30157383), the safety and tolerability arm of the same programme at the same 15 mg dose, found gastrointestinal symptoms improved on treatment and on placebo alike, so it is not a positive-outcome trial. Grubb 2020 PHAGE-2 (PMID 32824480) gave the cocktail with Bifidobacterium animalis subsp. lactis BL04 and reported within-group change, so under the attribution rule it cannot set a range for the phage component. PubMed searched 2026-10-26; these are the only human trials of the cocktail indexed.30897686;30157383;32824480
Fructooligosaccharideshort-chain FOS (scFOS)5 gdigestive comfort in adults with minor functional bowel disorders; 5 g/d sc-FOS vs placebo for 6 weeks, randomised double-blind, n=105, intensity of digestive disorders fell 43.6% vs a 13.8% rise on placebo, P=0.026 (Paineau 2008, Br J Nutr) Added 2026-11-19 for the off-sample 1MD Complete Probiotics Platinum row, whose panel declares NutraFlora FOS at 50 mg. PubMed search 'short-chain fructooligosaccharides functional bowel disorders randomized' returned 9 records; Paineau 2008 is the only one testing FOS alone against placebo at a digestive outcome in humans. Others were mixed formulas (attribution rule), a fermentation study, or animal work. Single trial: first author affiliated with Nutri-Health SA; funding was not verifiable from the abstract and is recorded as unverified rather than asserted independent. Range rests on one dose; a wider search for further scFOS trials is open.17697398
Lactobacillus acidophilus DDS-1; Bifidobacterium lactis UABla-12live strains, each as a single-strain capsule10000000000 CFU/dayIBS abdominal pain severity and symptom severity; not less than 1 x 10^10 CFU/day of either strain for 6 weeks, randomised double-blind placebo-controlled three-arm trial, n=330 adults, Rome IV (Martoni 2020, Nutrients) Added 2026-11-19 for the off-sample 1MD BiomeMD row. First and last authors at UAS Laboratories, the strain supplier, so the weaker basis under the independence rule. Capsule potency was checked at manufacture and at the end of the study. The paper's introduction cites earlier trials of the same strains in functional constipation and lactose intolerance; not reviewed. PubMed search 'Lactobacillus acidophilus DDS-1 irritable bowel randomized' 2026-11-19 returned 2 records.32019158
Psyllium huskhusk powder10–20 gregularity / constipation (stool frequency or consistency); 10 g/d (5 g b.d.) vs placebo 8 wk, randomized, n=22 chronic idiopathic constipation, stool frequency 2.9 to 3.8/wk, consistency and stool weight improved, placebo unchanged (Ashraf 1995, PMID 8824651); 10 g psyllium in cookies twice daily = 20 g/d (dose per registry IRCT 6637) vs placebo cookies 12 wk, randomized single-blind, n=51 T2D with chronic constipation, constipation symptoms improved vs placebo (Noureddin 2018, PMID 30219432); same dose, 3-arm flaxseed/psyllium/placebo, n=77, stool consistency and symptoms improved vs placebo (Soltanian 2019, PMID 30661699) Independence: all academic by affiliation (Univ Nebraska; Isfahan Univ of Medical Sciences, registry lists Isfahan Endocrine and Metabolism Research Center as sole funder); Ashraf funding unverified. No P&G-authored trial used. Upper bound 20 g: abstracts say '10 g twice per day', registry confirms 10 g per dose, full papers not checked (unverified). Noureddin and Soltanian appear to report one Isfahan trial (same group, overlapping arms): treated as one trial (unverified). Set aside: McRorie 1998 PMID 9663731 (P&G, docusate comparator, no placebo); Cheng 2019 PMID 31117218 (3.5 g/d null vs placebo, DuPont/Danisco co-authors); Lai 2023 PMID 37078654 (psyllium arm had added oligosaccharides, attribution rule; no group-by-time effect on BMF); Cheskin 1995 PMID 7775727 (24 g/d n=10, frequency and consistency not significant); Major 2018 PMID 30062794 and Jalanka 2019 PMID 30669509 (21 g/d 6-7 d, MRI/microbiota/stool-water endpoints); Yang 2021 PMID 34081625 (positive vs placebo n=54, dose missing from retrievable full text, unverified); Tomas-Ridocci 1992 PMID 1520545 (positive n=20, dose not in abstract); Gabrielli 2016 PMID 26325116 (3.5 g/d positive, post-STARR surgical population; would lower dose_low to 3.5 if admitted); kiwifruit/prune/agave/mixed-fibre comparator trials PMIDs 36537785, 36235798, 34074830, 21323688, 37389917, 27125883 (no placebo); Marlett 1987 PMID 3565338 (no placebo arm). Search 2026-11-19: 'psyllium constipation randomized controlled trial' 66 records; '(psyllium OR ispaghula OR plantago ovata) AND constipation AND placebo' 48 records. Replaces the 2026-09-07 row that cited a meta-analysis (PMID 35816465), since a meta-analysis does not set a range.8824651;30219432;30661699
Psyllium huskhusk powder10 gdigestive health / GI symptoms (IBS adequate relief); 10 g/d vs 10 g rice-flour placebo 12 wk, randomized, primary care, n=275 IBS (85 psyllium), responders 57% vs 35% month 1 and 59% vs 41% month 2, IBS-SSS fell 90 vs 49 points at 3 months P=0.03 (Bijkerk 2009, BMJ, PMID 19713235) Independent by affiliation (UMC Utrecht); funding unverified. Prior 1987 PMID 3322956 (n=80 IBS, global improvement 82% vs 53%) and Jalihal 1990 PMID 2129822 (crossover n=20) are positive but dose not in abstract and full text not retrievable: unverified, not used. Set aside: Longstreth 1981 PMID 7018336 (null); pediatric trials PMIDs 27080737, 36136861, 42552504; Staudacher 2026 meta-analysis PMID 42600900 (supports psyllium, sets no dose). Search 2026-11-19: '(psyllium OR ispaghula) AND irritable bowel syndrome AND placebo AND randomized' 25 records.19713235
Wheat dextrinwheat dextrin (Benefiber; NUTRIOSE wheat grade)No range setno adequate human trial identified for regularity / constipation (stool frequency or consistency); search 2026-11-19: '(wheat dextrin OR NUTRIOSE OR Benefiber OR resistant dextrin) AND (constipation OR bowel OR stool OR laxation OR irritable)' 93 records, all screened; 'wheat dextrin[tiab] AND humans[MeSH]' 12 records; 'wheat dextrin randomized' 11 records; none is a positive placebo-controlled trial of wheat dextrin alone on stool frequency or consistency Human wheat dextrin trials found were tolerance, mineral, energy or microbiota studies: van den Heuvel 2004 PMID 15220947 (Roquette-commissioned; 60 g/d lowered defecation frequency), Pasman 2006 PMID 16482066, Marteau 2011 PMID 20849371 (50 g single day, no difference vs placebo), Lefranc-Millot 2012 PMID 22429361 (Roquette), Armas 2011 PMID 22117983, Vermorel 2004 PMID 15309452 (100 g/d, not a constipation RCT), Barber 2022 PMID 36364873 (uncontrolled). Di Minno 2026 PMID 42369644 positive but multi-fibre formula (attribution rule). P&G-authored reviews PMIDs 27863994, 27680987 say wheat dextrin is not laxative and may constipate: competitor-authored, recorded only. No GSK/Haleon-authored Benefiber trial found. 'Benefiber' in PMIDs 15665181 and 11144434 is PHGG (Novartis formula), not wheat dextrin.—
Wheat dextrinwheat dextrin (Benefiber; NUTRIOSE wheat grade)No range setno adequate human trial identified for digestive health / GI symptoms; same three searches 2026-11-19 (93, 12, 11 records); only tolerance studies, no positive symptom trial See the regularity row for the trials found and set aside.—
Partially hydrolyzed guar gumPHGG (Sunfiber)5 gregularity / constipation; 3 or 5 g/d vs placebo 8 wk, randomized double-blind parallel, n=60 randomized / 51 analysed, adults with subjective constipation (2-5 defecations/wk), change in defecation frequency at 8 wk greater on 5 g than placebo (Dunnett vs placebo), 3 g not significant, baseline frequency higher in placebo arm (Abe 2023, J Clin Biochem Nutr, PMID 36936875) Weaker basis: manufacturer-authored (4 of 7 authors Taiyo Kagaku, maker of Sunfiber). No independent positive trial on frequency or consistency: Chan 2022 PMID 35297467 (5 g/d, n=52 care-home residents, no difference in bowel frequency or stool form vs water control; laxative use lower weeks 3-4) and Belo 2008 PMID 18425236 (10 g/d inpatients, no added effect) both null on this outcome. Yasukawa 2019 PMID 31509971 (Taiyo-funded, 5 g/d, n=44 diarrhoea-prone adults, stool form better than placebo only at weeks 7 and 11, no between-group multiplicity correction, frequency null): not used. Set aside: Ustundag 2010 PMID 21331988 (children, lactulose comparator); Waitzberg 2012 PMID 22566311 (inulin+PHGG blend, null); Altunsaray 2026 PMID 42400993 (PHGG+LGG synbiotic). Search 2026-11-19: 'partially hydrolyzed guar gum constipation randomized' 8 records; '(partially hydrolyzed guar gum OR PHGG OR Sunfiber) AND (constipation OR defecation OR bowel movement OR irritable bowel) AND (placebo OR randomized OR randomised)' 14 records.36936875
Partially hydrolyzed guar gumPHGG6 gdigestive health / GI symptoms (IBS bloating); 6 g/d vs placebo 12 wk, randomized double-blind, n=121 IBS randomized / 108 ITT, journal bloating score -4.1 vs -1.2 (P=0.03) and bloating+gas score improved, effect held 4 wk after stopping (Niv 2016, Nutr Metab, PMID 26855665) Independent by affiliation (Tel Aviv Sourasky); funding and product source unverified. Caveat: IBS severity score, QoL and other symptoms null; whether bloating was the prespecified primary and whether multiplicity was adjusted not verified. Set aside: Parisi 2002 PMID 12184518 and Parisi 2005 PMID 15986863 (open-label, no placebo); Romano 2013 PMID 23345946 (pediatric); Wierzbicka 2025 PMID 40693198 (PHGG+probiotics+polyphenols). Searches as the regularity row.26855665
Inulinhighly polymerized inulin (source unverified)12 gregularity / constipation; inulin 12 g per 300 mL apple juice vs placebo juice, randomized placebo-controlled, n=20 adults 20-29 with chronic constipation symptoms, bowel movement frequency rose and defecation eased (Glibowski 2020, Food Funct, PMID 32319465) Independent by affiliation (Univ of Life Sciences, Lublin): the independent trial at the same 12 g/d dose as the manufacturer-co-authored Puhlmann 2025 and Micka 2017 rows. Unverified: daily volume (12 g/d assumes 300 mL/d), funding, inulin source, duration (abstract only). Marteau 2011 PMID 21091293 (15 g/d chicory inulin, n=50 elderly, defecation difficulty and satisfaction improved; frequency/consistency not reported in abstract; co-author affiliations not in PubMed record, possible producer link unverified): would raise dose_high to 15 if admitted. Buddington 2017 PMID 29258261 (oligofructose 15 g/d, BENEO): manufacturer, different fraction. Set aside: Hunter 1999 PMID 10395619 (6 g/d oligofructose null in IBS); pediatric and synbiotic trials PMIDs 32998471, 27931142, 27782892, 27776217; inulin+resistant maltodextrin milk PMID 18372941 (attribution). Search 2026-11-19: '(inulin OR chicory OR oligofructose) AND (constipation OR stool frequency OR bowel movement) AND (placebo OR randomized)' 87 records (not fully screened); '(inulin OR chicory OR oligofructose) AND constipation AND Randomized Controlled Trial[pt]' 25 records, all screened.32319465
Inulininulin/oligofructose 50:509.2 gdigestive health / GI symptoms (IBS-C); 4.6 g twice daily vs maltodextrin 8 wk, randomized single-blind, n=34 IBS-C, primary IBS-SSS group x time interaction P=0.047 (267 to 196), IBS-QoL improved; Bristol stool type not different between groups (Akcali 2025, Sci Rep, PMID 41034384) Independent by affiliation (Mardin Artuklu and Ankara universities); funding unverified. Blend of two chain-length fractions of the same inulin-type fructan, not different ingredients, so not treated as a multi-ingredient formula under the attribution rule. Not a regularity trial: stool form null between groups. Searches as the regularity row.41034384
Polydextrosepolydextrose8–10 gregularity / constipation; 8 g/d vs placebo, randomized, n=45 healthy, orofaecal transit shortened and stool consistency improved in constipated subjects (Hengst 2009, Int J Food Sci Nutr, PMID 19107626); 10 g/d vs control 8 wk, randomized triple-blind, n=50 haemodialysis outpatients on laxatives, primary stool frequency rose 3.0 to 7.5/wk (Shimada 2015, J Nutr Sci Vitaminol, PMID 26440643) Both independent by affiliation (Univ Jena; Hidaka Rehabilitation Hospital); funding unverified. Hengst consistency result is a constipated subgroup per the corrected abstract. Excluded pending check: Jie 2000 PMID 11101478 (4, 8, 12 g/d, bowel frequency and ease improved; co-author affiliation not in PubMed record, possibly the polydextrose producer, unverified; which doses significant not in abstract); if admitted, range 4-12. Timm 2013 PMID 23427334 (20 g/d crossover n=36 healthy, more stools/day and softer stools vs low-fibre control; co-author affiliations not in PubMed record, possible industry, unverified); if independent, dose_high 20. Set aside: Ibarra 2019 PMID 30791557 (DuPont/Danisco authors; primary transit null); Duncan 2018 PMID 30029461 (Nestle; 8/12 g null on transit, frequency, consistency); Borges 2023 PMID 37321430 (within-group only); Lai 2023 PMID 37078654, Magro 2014 PMID 25056655, PMID 31209720 (blends); pediatric formula trials. Search 2026-11-19: 'polydextrose AND (constipation OR stool OR bowel OR defecation OR laxation) AND (placebo OR randomized OR randomised)' 57 records (not fully screened); 'polydextrose AND (constipation OR bowel function OR defecation OR stool frequency) AND (Randomized Controlled Trial[pt] OR placebo)' 20 records, all screened.19107626;26440643
PolydextrosepolydextroseNo range setno adequate human trial identified for digestive health / GI symptoms; same searches 2026-11-19 (57 and 20 records); Duncan 2018 PMID 30029461 improved PAC-SYM stool and rectal subscores at 4 wk on 8 g only as secondary outcomes with a null primary (Nestle); Ibarra 2019 secondary inventories vs baseline only (DuPont) Neither sets a range under the positive-outcome rule.—
Pectinpectin (citrus or apple not stated in abstract)24 gregularity / constipation; 24 g/d vs maltodextrin 4 wk, randomized placebo-controlled, n=80 slow-transit constipation, colonic transit 60.2 vs 79.4 h and constipation score better than placebo (Xu 2014, Zhonghua Yi Xue Za Zhi, PMID 25623312) Independent by affiliation (Jinling Hospital, Nanjing); funding, pectin source and whether the constipation score includes frequency or consistency unverified (Chinese full text not checked). Set aside: Koyama 2022 PMID 35971232 (prune juice: sorbitol+pectin+polyphenol, attribution); Di Minno 2026 PMID 42369644 (multi-fibre); diarrhoea, enteral and pediatric trials. Search 2026-11-19: 'pectin AND (constipation OR stool frequency OR bowel movement OR irritable bowel) AND (placebo OR randomized OR randomised)' 22 records, all screened.25623312
Pectinpectin (source unverified)24 gdigestive health / GI symptoms (IBS-D); 24 g/d vs placebo 6 wk, randomized, n=87 IBS-D, composite symptom score and Bristol score reduced and IBS-QoL improved vs placebo (Xu 2015, Zhonghua Wei Chang Wai Ke Za Zhi, PMID 25809332) Same Jinling Hospital group as the regularity row; independence and funding as there (unverified). Search as the regularity row.25809332
Acacia gumacacia fiber10 gregularity / constipation; 10 g/d (5 g first 5 days) vs maltodextrin 4 wk, randomized double-blind 3-arm, n=180 IBS-C (55 acacia analysed), primary stool frequency higher than placebo P<0.001 (Bonferroni-corrected); stool consistency and mass null (JanssenDuijghuijsen 2024, Eur J Nutr, PMID 38653808) Weaker basis: a co-author is at Nexira, maker of the product tested. A correction notice exists (PMID 40119929), content not checked (unverified). Independent: Jarrar 2021 PMID 33435475 (20 g/d) reports only self-perceived bowel-movement quality, so it is placed in the digestive row; would raise dose_high to 20 if admitted here. Set aside: Min 2012 PMID 22969230 (acacia + B. lactis yogurt, attribution); Calame 2008 PMID 18466655 (Kerry, microbiota); Bliss 2001 PMID 11480529 and 2014 PMID 25155992 (faecal incontinence). Search 2026-11-19: '(acacia gum OR gum arabic OR acacia senegal OR acacia fiber) AND (constipation OR stool OR bowel OR irritable bowel) AND (placebo OR randomized OR randomised)' 34 records, all screened.38653808
Acacia gumgum arabic (Acacia senegal)20 gdigestive health / GI symptoms; 20 g/d vs 1 g pectin placebo 12 wk, randomized single-blind, n=80 randomized / 61 completed, adults with or at risk of metabolic syndrome, self-reported bloating and bowel-movement quality improved (Jarrar 2021, Nutrients, PMID 33435475) Independent by affiliation (UAE Univ, Victoria Univ); funding unverified. Whether the GI improvements are between-group or within-group not verified. JanssenDuijghuijsen 2024 found IBS-SSS null for acacia. Search as the regularity row.33435475
Glucomannankonjac glucomannan3–4 gregularity / constipation; 3 and 4 g/d vs placebo, randomized double-blind crossover, n=60 'changes in intestinal habit', evacuations +3/wk at 3 g and +6/wk at 4 g, placebo no change (Marsicano 1995, G E N, PMID 8566676); KGM vs maltodextrin 8 wk, randomized double-blind, n=48 elite male athletes with Rome IV functional constipation, BMF, PAC-SYM, PAC-QoL, BFI improved vs placebo (Zhu 2025, Eur J Nutr, PMID 41117955) Both independent by affiliation (Hospital Vargas de Caracas; Southwest Univ); funding unverified. Zhu dose 3 g/d comes from a trade-press report, not the paper (unverified). Marsicano is Spanish-language; whether subjects were constipated is not stated in the abstract. Set aside: Chen 2006 PMID 17027233 and Chen 2008 PMID 18460488 (non-randomized placebo-then-KGM sequence); pediatric Staiano 2000 PMID 10636972, Loening-Baucke 2004 PMID 14993586, Chmielewska 2011 PMID 21320737; Passaretti 1989 PMID 2547312 (transit only). Search 2026-11-19: '(glucomannan OR konjac) AND (constipation OR stool OR bowel movement OR defecation) AND (placebo OR randomized OR randomised)' 17 records, all screened.8566676;41117955
Glucomannankonjac glucomannanNo range setno adequate adult human trial identified for digestive health / GI symptoms; same search 2026-11-19, 17 records; only a pediatric abdominal-pain trial PMID 23716985 found Pediatric weight-based dosing, not used for adult products.—
Soluble corn fibersoluble corn fiber (Promitor)No range setno adequate human trial identified for regularity / constipation or digestive health; Timm 2013 PMID 23427334 (20 g/d, n=36, faecal wet weight up but stool frequency and softness not different from control); Stewart 2010 PMID 20090313 (12 g/d crossover n=20, no stool weight change); Housez 2012 PMID 22672058 and Maathuis 2013 PMID 23388502 tolerance or null; search 2026-11-19: '(soluble corn fiber OR resistant maltodextrin OR resistant dextrin OR Fibersol OR Promitor) AND (constipation OR bowel movement OR defecation OR stool frequency OR laxation) AND (randomized OR placebo)' 24 records, all screened Set aside on outcome grounds, not independence.—
Resistant maltodextrindigestion-resistant maltodextrin (Fibersol-2)No range setno qualifying human trial identified in PubMed for stool frequency or consistency; Asto 2016 PMID 26437831 (15 g/d 21 d, n=66, colonic transit shortened vs placebo but defecation frequency rose in both arms and consistency improved only within the RMD arm); Burns 2018 PMID 30527258 (stool wet weight only); search as the soluble corn fiber row, 2026-11-19 A manufacturer-coauthored 2018 meta-analysis (PMID 29535547) reports a pooled rise in stool frequency; a meta-analysis does not set a range and its trials were not retrieved. Asto 2016 sponsor not stated in retrieved text (unverified).—

Download the CSV →

Known limitations

A dose range is only as good as the paper it came from. Where a source turned out to contain a problem that could not be resolved from its full text, the problem is recorded against the row rather than quietly dropped, and the row stays in the table so the judgment can be checked. 24 of 55 rows have no range set at all; each one records why, and criterion 4 cannot be scored from them.

!
L-glutamine (free-form) — PMID 39397201

UNRESOLVED: the subgroup statistic is printed as WMD -0.01 with 95% CI -0.10 to -0.08 (n=5 studies), an interval that excludes its own point estimate; full text gives no way to determine the correct figures. SEPARATE INCONSISTENCY: Table 1 defines duration subgroups as ≥4 weeks / <4 weeks, but the Discussion/Conclusion instead describe the significant effect as occurring in interventions "less than 2 weeks" -- a cutoff absent from the paper's own methodology. Flag this if this row is ever used for a duration-based judgment, not just dose.